SCHEMBL4534233

SCHEMBL4534233

Cc1cccc(SC(C(=O)NO)c2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.57
MAPT P10636 7/20 0.54
PKM P14618 1/20 0.54
ALDH1A1 P00352 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
ADAM17 P78536 1/20 0.50
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
PAX8 Q06710 1/20 0.49
EPHX1 P07099 1/20 0.48
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
NPSR1 Q6W5P4 3/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4533599 0.88 LMNA (0.56) LMNAMAPTPKMALDH1A1L3MBTL1
SCHEMBL2846675 0.85 LMNA (0.72) LMNAMAPTPKMALDH1A1L3MBTL1
SCHEMBL4533381 0.84 LMNA (0.55) LMNAMAPTPKMALDH1A1L3MBTL1
SCHEMBL4536275 0.83 LMNA (0.54) LMNAMAPTPKMALDH1A1L3MBTL1
SCHEMBL4535734 0.83 EPHX1 (0.70) LMNAMAPTPKMALDH1A1L3MBTL1
SCHEMBL4540229 0.83 LMNA (0.54) LMNAMAPTPKMALDH1A1L3MBTL1
SCHEMBL4532011 0.82 MAPT (0.60) LMNAMAPTPKMALDH1A1L3MBTL1
SCHEMBL8114387 0.80 ATM (0.51) LMNAMAPTPKMALDH1A1L3MBTL1
SCHEMBL2839882 0.79 ADAM17 (0.55) LMNAMAPTPKMALDH1A1L3MBTL1
SCHEMBL4533793 0.78 LMNA (0.54) LMNAMAPTPKMALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 LMNA 424/4885MAPT 1533/4885PKM 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.